Immunogenicity, clinical efficacy, and safety of the sinopharm (BBIBP-CorV) SARS-CoV-2 vaccine among people with multiple sclerosis receiving disease-modifying therapies: a prospective cohort study

Table 2 BBIBP-CorV vaccine adverse events and post-vaccination MS activity

Variable	Level	Total cohort (N = 209)
Non-serious adverse events^†	yes	138 (66.0)
	fever (< 40°c)	43 (20.6)
	injection site pain	36 (17.2)
	fatigue/malaise	34 (16.3)
	headache	34 (16.3)
	myalgia	24 (11.5)
	chill	17 (8.1)
	anorexia	8 (3.8)
	nausea/vomiting	7 (3.4)
	arthralgia	4 (1.9)
	dizziness	4 (1.9)
	vertigo	3 (1.4)
	nasal congestion/sore throat	2 (1.0)
Serious adverse events^‡	yes	0
MS activity ≤ 12 w of vaccination	yes	14 (6.7)
	between V₁ and V₂	3 (1.4)
	after V₂	11 (5.3)
	< 6 weeks	10 (4.8)
	6–12 weeks	4 (1.9)

Note: The frequency (%) was used to describe categorical data. Abbreviations: MS: multiple sclerosis; SARS-CoV-2: severe acute respiratory syndrome coronavirus 2; V₁: 1st dose of vaccine; V₂: 2nd dose of vaccine
† Each participant might have reported multiple adverse events following vaccination
‡ Serious adverse events were defined as anaphylaxis, thrombosis with thrombocytopenia syndrome, Guillain–Barré syndrome, myocarditis, pericarditis, and events requiring hospital admission (except for MS disease activity, which was separately evaluated)

ISSN: 1471-2377